

# Clinical characteristics and prognosis of Neuro-Behçet's disease

Mine Hayriye Sorgun<sup>1</sup> , Mustafa Aykut Kural<sup>2</sup> , Canan Yücesan<sup>1</sup> 

## Abstract

**Objective:** Neuro-Behçet's disease (NBD) is a rare manifestation of Behçet's disease (BD) and may cause severe disability. The aim of this study was to evaluate the treatment response in patients with NBD and to investigate the parameters that may influence the prognosis of the disease in patients with severe to mild-moderate disability.

**Methods:** The files of 60 patients admitted to our outpatient clinic for NBD between January 2007 and June 2014 were retrospectively reviewed. We compared the BD duration, time to NBD, NBD type and course, clinical findings of BD, functional neurological system involvement, localization of lesions on brain MRI, and all the medications between the severe and mild-moderate disability groups.

**Results:** The mean time to the onset of NBD was significantly longer ( $17.8 \pm 4.6$  years) and the mean age was significantly higher ( $50.25 \pm 9.1$  years) in patients with severe disability than in those with mild-moderate disability ( $7.5 \pm 8.0$  years and  $37.5 \pm 10.9$  years;  $p=0.01$  and  $p=0.03$ , respectively). Moreover, hemispheric involvement was significantly associated with severe disability ( $p=0.006$ ). No difference was found with regard to other investigated parameters between the groups.

**Conclusion:** We believe that severe neurological disability may be associated with older age at the onset of NBD or longer time to NBD and hemispheric lesions on brain MRI. However, our results should be cautiously evaluated with further research.

**Keywords:** Neuro-Behçet's disease, neurological involvement, functional system involvement, cranial MRI lesions, prognosis



### ORCID IDs of the authors:

M.H.S. 0000-0003-2370-7319;  
M.A.K. 0000-0003-2540-6712;  
C.Y. 0000-0001-8999-5355.

**Cite this article as:** Sorgun MH, Kural MA, Yücesan C. Clinical characteristics and prognosis of Neuro-Behçet's disease. *Eur J Rheumatol* 2018; 5: 235-9.

<sup>1</sup> Department of Neurology, Ankara University School of Medicine, İbni Sina Hospital, Ankara, Turkey

<sup>2</sup> Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark

### Address for Correspondence:

Mine Hayriye Sorgun, Department of Neurology, Ankara University School of Medicine, İbni Sina Hospital, Ankara, Turkey

E-mail: drmsorgun79@hotmail.com

Submitted: 2 March 2018

Accepted: 15 May 2018

Available Online Date: 10 October 2018

Copyright © Author(s) - Available online at [www.eurjrheumatol.org](http://www.eurjrheumatol.org).

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



## Introduction

Behçet's disease (BD) is an inflammatory disorder of unknown etiology, characterized by recurrent aphthous stomatitis, genital ulceration, and uveitis triad. It was first described by Hulusi Behçet (1). The highest incidence of BD has been observed in the Middle East, Mediterranean basin, and Far East region (2). Its diagnosis has been based on the International Diagnostic Criteria for BD (3). Although the neurological involvement of BD is a rare manifestation, it is one of the most serious causes of long-term morbidity. NBD is more common in males, and neurological involvement usually develops after the onset of other systemic manifestations within 3-6 years. In only 6% of patients, neurological involvement may be the first symptom of BD (4, 5). Common involvement patterns include focal parenchymal lesions, vascular thrombosis, arterial vasculitis, aseptic meningoencephalitis followed by intracranial aneurysm, extracranial aneurysm/dissection, optic neuropathy, and tumor-like NBD (3, 6).

Treatment for an acute attack of NBD includes steroids, whereas preventive treatment includes prednisolone, azathioprine, cyclophosphamide, chlorambucil, methotrexate, etanercept, and infliximab administration (4, 7-14). The aim of this study was to evaluate the treatment response in patients with NBD and to compare the parameters that may influence the prognosis of the disease in patients with severe to mild-moderate disability.

## Methods

The files of patients admitted to our outpatient clinic for NBD between January 2007 and June 2014 were retrospectively reviewed. Approval was obtained from the research ethic committee in advance of the study. Written informed consent was obtained from all the patients who participated in this study. Before the diagnosis of NBD, we excluded other etiologies that may mimic NBD. None of the patients had any risk factors and etiological causes (large artery atherosclerosis, cardioaortic embolism, and small artery occlusions) for cerebral vascular disease. The diagnosis of BD was made according to the criteria set by the International Study Group for Behçet's Disease (3).

**Table 1.** Epidemiological and clinical characteristics of patients with NBD

	Total NBD n=60	Mild-moderate NBD n=56	Severe NBD n=4	p
Age, year, mean±SD	45.42±11.73 (21-70)	44.8±11.7 (21-70)	53.8±9.1 (43-65)	0.1
Sex, n (%)				
Female	23 (38.3)	22 (39.3)	1 (25)	0.5
Male	37 (61.7)	34 (60.7)	3 (75)	
Onset age of BD	30.33±10.1 (14-56)	30.18±10.3 (14-56)	32.52±6.55 (27-42)	0.6
Age at onset of NBD	38.37±11.2 (16-62)	37.5±10.9 (16-61)	50.25±9.1 (42-62)	0.03
NBD type				
- Parenchymal, n (%)	48 (80)	44 (78.6)	4 (100)	0.3
- CVT, n (%)	6 (10)	6 (10.7)	0 (0)	0.5
- Parenchymal+CVT, n (%)	2 (3.3)	2 (3.6)	0 (0)	0.7
- Pseudo tumor cerebri, n (%)	4 (6.7)	4 (7.1)	0 (0)	0.6
BD duration (year), mean±SD (Min-Max)	15.08±8.94 (2-42)	14.6±9.1 (2-42)	21.3±3.9 (16-25)	0.09
Time to NBD (year) Mean±SD (Min-Max)	8.2±8.2 (0-32)	7.5±8.0 (0-32)	17.8±4.6 (13-23)	0.01
Parenchymal NB course, n (%)				
- Relapsing form	54 (90)	52 (92.9)	2 (50)	0.4
- Progressive form	6 (10)	4 (7.1)	2 (50)	
Functional system involvement				
Pyramidal (+)	32 (53.3)	28 (50)	4 (100)	0.12
Brain stem (+)	17 (28.3)	15 (26.8)	2 (50)	0.3
Sensory (+)	23 (38.3)	22 (39.3)	1 (25)	0.5
Bowel and bladder functions (+)	3 (5)	3 (5.4)	0 (0)	0.8
Visual (+)	3 (5)	3 (5.4)	0 (0)	0.8
Cerebellar (+)	21 (35)	19 (33.9)	2 (50)	0.4
Mental (+)	3 (5)	3 (5.4)	0 (0)	0.8
HLA B51, n=30	3 (5)	3 (5.4)		
Findings of BD, n (%)				
- Oral aphthous ulcers	60 (100)	56 (100)	4 (100)	0.9
- Genital ulcer	46 (76.6)	42 (75)	4 (100)	0.6
- Uveitis	34 (56.67)	31 (55.4)	3 (75)	0.6
- Pathergytest, n=54	31 (51.67)	28 (50)	3 (75)	0.6
- Arthritis	29 (48.3)	28 (50)	1 (25)	0.6
- Skin involvement	27 (45)	26 (46.4)	1 (25)	0.6
- DVT	10 (16.6)	10 (17.9)	0 (0)	0.9
- GIS involvement	6 (10)	6 (10.7)	0 (0)	0.9
- Epididymitis	2 (3.2)	2 (3.6)	0 (0)	0.9
- Lung involvement	1 (1.6)	1 (1.8)	0 (0)	0.9
- Thrombophlebitis	1 (1.6)	1 (1.8)	0 (0)	0.9
MRI, n (%)				
- Brainstem	36 (60)	27 (48.2)	4 (100)	0.11
- Thalamus	9 (15)	8 (14.3)	1 (25)	0.6
- Cerebellum	6 (10)	5 (8.9)	1 (25)	0.4
- Hemisphere	18 (30)	14 (25)	4 (100)	0.006
Treatment, n (%)				
- Colchicine	46 (76.6)	42 (75)	4 (100)	0.6
- Prednisolone	12 (20)	11 (19.6)	1 (25)	0.9
- Azothioprine	34 (56.67)	31 (55.4)	3 (75)	0.6
- Diazomide	2 (3.2)	2 (3.6)	0 (0)	0.9
mRS at last examination, median (Min-Max) mean±SD	1 (0-5) 1.47±1.27	1 (0-3) 1.27±1.1	4 (4-5) 4.3±0.5	<0.001

BD: Behçet's disease; NBD: Neuro-Behçet's disease; SD: Standarddeviation;mRS: Modified Rankin Scale; CVT: Cerebral venous thrombosis; DVT: Deep venous thrombosis; GIS: Gastrointestinal system

**Table 2.** Epidemiological and clinical characteristics of patients with severe disability

Case No	Age (years)/ sex	Duration of BD/time to NBD (years)/ Age at onset age of NBD	CNS involvement	Disease course	Neurological findings	MRI lesions	Follow up mRS
1	55/M	25/23/30	Parenchymal	Relapsing type	Pyramidal Brainstem Cerebellar	Brainstem Cerebellum Hemisphere	5
2	65/M	23/20/42	Parenchymal	Relapsing type	Pyramidal Brainstem Visual	Brainstem Thalamus Hemisphere	4
3	52/F	21/13/31	Parenchymal	Progressive type	Pyramidal Cerebellar Sensory	Brainstem Hemisphere	4
4	43/M	16/15/27	Parenchymal	Progressive type	Pyramidal Visual	Brainstem Hemisphere	4

M: Male; F:Female; CNS: Central nervous system; BD: Behçet's disease; NBD: Neuro-Behçet's disease; mRS: Modified Rankin Scale

For each NBD patient, information such as the age, sex, clinical findings of BD, date of diagnoses of BD and NBD, type and course of NBD, all medications, and functional neurological system involvement (assessed using the Kurtzke Functional System Scale for each system) was collected. BD duration was defined as the time from diagnosis of BD to the last examination. Period from the diagnosis of BD to the onset of the symptoms of NBD was defined as the time to NBD.

The severity of NBD was evaluated using the modified Rankin Scale (mRS) scores at the last examination. The mRS score is commonly used for measuring the degree of disability or dependence in the daily activities of individuals who have suffered a stroke or have other causes of neurological disability (0: no symptoms; 1: no significant disability; 2: slight disability; 3: moderate disability; 4: moderately severe disability; 5: severe disability; 6: dead). In addition, the localization of lesions on brain magnetic resonance imaging (MRI) was also recorded.

The patients with mRS scores of 0-3 at the last examination were included in the mild-moderate disability group and those with scores of 4-6 in the severe disability group. We compared the BD duration, time to NBD, type and course of NBD, clinical findings of BD, functional neurological system involvement, localization of lesions on brain MRI, all medications, and mRS scores at the last examination in the severe and mild-moderate disability groups.

#### Statistical analysis

Qualitative variables were presented with their distribution of frequencies and are summarized as the mean and standard deviation (SD). Group rates were compared using the chi-square test and means using the Mann-Whit-

ney U test. A p value of <0.05 was considered statistically significant. The statistical analysis was performed using the Statistical Package for Social Sciences, version 11.5 (SPSS Inc.; Chicago, IL, USA).

#### Results

A total of 60 patients with BD [37 male (61.7%) and 23 female (38.3%); mean age, 45.42±11.73 (21-70) years] were diagnosed as having neurological involvement. The mean duration of BD was 15.08±8.94 (2-42) years and that of NBD was 7.05±8.94 (2-18) years. Among the patients with NBD, 48 (80%) had parenchymal involvement, 6 (10%) had cerebral venous thrombosis (CVT), 2 (3.3%) had parenchymal involvement with CVT, and 4 (6.7%) had pseudotumor cerebri. Non-neurological involvements included oral ulcers (n=60), genital ulcer (n=46), uveitis (n=34), arthritis (n=29), skin involvement (n=27), deep venous thrombosis (DVT; n=10), gastrointestinal system (GIS) involvement (n=6), epididymitis (n=2), lung involvement (n=1), and thrombophlebitis (n=1). Fifty-four patients (90%) had a relapsing course, and 6 (10%) had a progressive course. The most common functional system involvement was pyramidal (n=32), which was determined using the Kurtzke Functional System Scale in recent neurological examinations. Sensory (n=23), cerebellar (n=21), brain stem (n=17), visual (n=3), and mental (n=3) functional system involvements were also observed (Table 1). The mean mRS score was 1.62(0-5) in males and 1.22(0-4) in females; the difference was not statistically significant (p=0.17; Table 1).

The lesions on brain MRI were located in the brainstem (n=36), thalamus (n=9), cerebellum (n=6), or hemisphere (n=18) (Table 1). All the patients were treated with prednisolone in case of an acute attack. As a prophylactic treat-

ment, 34 patients were administered azathioprine and 12 were administered oral prednisolone (Table 1).

While 56 cases had mild-moderate disability, 4 had severe disability. The mRS score was 4 in 3 patients and 5 in 1 patient with severe disability; 2 had a progressive and others had a relapsing course; 3 of 4 patients were male, and 1 was female. The mean age at the onset of NBD was 37.5±10.9 years in the mild-moderate disability group and 50.25±9.1 years in the severe disability group; the difference was statistically significant (p=0.03). The mean time to NBD was significantly longer (17.8±4.6 years) in patients with severe disability than in those with mild-moderate disability (7.5±8.0 years; p=0.01). All the patients with severe disability had parenchymal involvement, as seen on brain MRI, and pyramidal signs on examination (Table 2). Moreover, hemispheric involvement was significantly associated with severe disability (p=0.006). No differences were found in the age of BD onset, sex, mean duration of BD, type and course of NBD, clinical findings of BD, neurological functional system involvement, and treatment modalities between the groups (p>0.05 for each; Table 1).

#### Discussion

To date, 260 patients with NBD have been reported in the English literature (4, 7-13, 15-32). Males have been the dominant category in most of these studies (4, 7-9, 11, 12, 15-32); however, in some series, either females have been the dominant category (13, 20, 26) or there were no differences based on sex (10). In the present study, we found that males (n=37, 61.7%) were more affected than females (n=23, 38.3%), which is in agreement with all previous Turkish studies as well as most other studies. We also found that pyramidal signs were the

most common neurological findings in parenchymal NBD, which is in agreement with previous studies (4, 8, 11-13, 29-31).

Akman-Demir et al. (4) reported the clinical features of 200 NBD cases. In their study, 157 patients received intravenous (IV) high-dose corticosteroids at the time of acute attacks and oral maintenance therapy thereafter. Cyclophosphamide (n=52), azathioprine (n=63), chlorambucil (n=5), and methotrexate (n=2) were administered for preventive treatment [4]. Gökçay et al. (29) identified 54 patients with NBD; they used IV methylprednisolone (1 g/day for 7 days) during the acute stage and cyclophosphamide therapy (750-1000 mg/month) during the follow-up for patients with parenchymal involvements. Patients with vascular BD were treated with anticoagulants (29).

In summary, in almost all the studies published to date, parenchymal NBD has been reported to be treated with prednisolone during acute attacks. It has been suggested that steroids should be given at least 6 months after an acute attack, and appropriate preventive treatment should be started as soon as possible after the diagnosis of NBD (32). Colchium, prednisolone, azathioprine, cyclophosphamide, chlorambucil, methotrexate, etanercept, and infliximab have been given after an acute attack to prevent recurrence (4, 9-14, 23, 27). It is known that cyclosporin is effective for the treatment of ocular BD, but it may be associated with a higher risk for NBD development; therefore, cyclosporine should not be used for the treatment of NBD (33-36). Diazomid and lumboperitoneal shunts have been reported to be beneficial for reducing intracranial hypertension (7, 10). Warfarin and acetylsalicylic acid have been given for CVT treatment (7-10).

Akman-Demir et al. (4) reported that one-third of their patients had severe sequelae due to NBD. Parenchymal involvement, elevated protein level and/or pleocytosis in CSF, brainstem involvement with other brain regions, primary or secondary progressive course, and relapse during steroid tapering were associated with a poor prognosis (4). Siva et al. (19) reported that 45.1% of patients with NBD had EDSS of  $\geq 6$  (indicating the need of a walking aid) in 10 years from the onset of BD. Cerebellar symptoms at the onset or progressive course were associated with unfavorable outcomes, whereas a headache at the onset or diagnosis of CVT was associated with favorable outcomes (19). In contrast to these reports, in our study population, only 7% of patients had severe disability. In agreement with previous treatment recommendations (32), all our patients were

treated with oral or IV high-dose prednisolone in case of acute attacks. Steroid treatment was continued for at least 6 months after acute attacks, immediately followed by preventive treatment; therefore, we did not observe any recurrence due to early steroid tapering. Because only a small percentage (7%) of our patients had a poor outcome, we speculated that the recommended treatment modality resulted in a better prognosis, unlike in previous reports that showed a worse prognosis (4, 19). Peno et al. (13) suggested that delayed treatment and younger age could lead to an aggressive disease. In contrast to Peno et al. (13), we found that older age at the onset of NBD had a worse prognosis. This issue should be evaluated with further research. We also found that the time to NBD was longer in the severe disability group than in the mild-moderate disability group. Probably, when NBD begins at an older age, the time to NBD becomes longer; therefore, both age at the onset of NBD and time to NBD may have the same implications.

In other words, when brain involvement is seen relatively early based on the onset of BD or when NBD begins at a younger age, the response to the suggested treatment modality may be better; therefore, the prognosis may also be better. Conversely, when NBD is seen later based on the onset of BD or when NBD begins at an older age, the response to the suggested treatment modality may not be sufficiently good; therefore, the outcome may be worse.

Brainstem involvement has been most commonly reported in patients with parenchymal NBD, followed by hemispheric, basal ganglia, thalamus, and spinal cord involvement, which is compatible with our study (4, 8, 10, 11, 17, 18, 20, 21, 23, 25, 29, 30-32). We found that hemispheric lesions were predominant in patients with severe NBD compared with mild-moderate NBD ( $p=0.006$ ). Therefore, severe disability may be associated with hemispheric lesions on brain MRI.

In conclusion, severe neurological disability may be associated with older age at the onset of NBD or longer time to NBD and hemispheric lesions on brain MRI. Our results confirmed the success of previous treatment recommendations which stated that high-dose steroids should be immediately administered in case of an acute NBD attack, steroid treatment should be continued for at least 6 months after the attack, and other immunosuppressive agents should also be administered after the attack to prevent recurrence and progression of NBD in patients with younger age or those with a

shorter time to NBD. However, in patients with an older age at the onset of NBD or in those with a longer time to NBD, this treatment modality may be unsuccessful. However, our results should be cautiously evaluated because our severe disability group included only four cases; to decide whether the results represent all the older onset NBD or longer time to NBD cases, further research that includes more patients with severe disability is needed.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the Ankara University Ethical Committee (Decision Date: 15/04/2015; Decision No.: 211-7023)

**Informed Consent:** Written informed consent was obtained from all the patients who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - C.Y., M.H.S., M.A.K.; Design - C.Y., M.H.S., M.A.K.; Supervision - C.Y.; Resource - C.Y.; Materials - C.Y., M.H.S., M.A.K.; Data Collection and/or Processing - M.H.S., M.A.K.; Analysis and/or Interpretation - C.Y., M.H.S., M.A.K.; Literature Search - C.Y., M.H.S., M.A.K.; Writing - C.Y., M.H.S., M.A.K.; Critical Reviews - C.Y.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

- Behçet H. Überresidivierende, aphtösedurchein Virus verursachte Geschwüre am Mund, am Auge und an der Genitalien. *DermWschr* 1937; 105: 1152-7.
- Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol* 2007; 3: 148-55. [CrossRef]
- Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, et al. Criteria for diagnosis of Behçet's disease. *Lancet* 1990; 335: 1078-80.
- Akman-Demir G, Serdaroglu P, Taşçi B, Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. *Brain* 1999; 122: 2171-81. [CrossRef]
- Al-Araji A, Kidd PD. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. *Lancet Neurol* 2009; 8: 192-204. [CrossRef]
- Dutra LA, Goncalves CR, Braga-Neto P, Pedrosa JL, Gabbai AA, Barsottini OG, et al. [http://www.ncbi.nlm.nih.gov/pubmed/?term=deSouzaAW%5BAuthor%5D&cauthor=true&cauthor\\_uid=22169955](http://www.ncbi.nlm.nih.gov/pubmed/?term=deSouzaAW%5BAuthor%5D&cauthor=true&cauthor_uid=22169955). Atypical manifestations in Brazilian patients with neuro-Behçet's disease. *J Neurol* 2012; 259: 1159-65. [CrossRef]

7. Farah S, Al-Shubaili A, Montaser A, Hussein JM, Malaviya AN, Mukhtar M, et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. *J NeurolNeurosurg Psychiatry* 1998;64: 382-4. [\[CrossRef\]](#)
8. Al-Fahad S, Al-Araji A. Neuro-Behçet's disease in Iraq: a study of 40 patients. *J NeurolSci* 1999;170: 105-11. [\[CrossRef\]](#)
9. Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D. Neurological manifestations of Behçet's disease in a Caribbean population: clinical and imaging findings. *J Neurol* 2002;249: 410-8. [\[CrossRef\]](#)
10. Joseph FG, Scolding NJ. Neuro-Behçet's disease in caucasians: a study of 22 patients. *Eur J Neurol* 2007;14: 174-80. [\[CrossRef\]](#)
11. Riera-Mestre A, Martínez-Yelamos S, Martínez-Yelamos A, Ferrer I, Pujol R, Vidaller A. Clinicopathologic features and outcomes of neuro-Behçet disease in Spain: A study of 20 patients. *Eur J Intern Med* 2010;21:536-41. [\[CrossRef\]](#)
12. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behçet's disease in Japan: a multicenter retrospective analysis. *Mod Rheumatol* 2012;22:405-13. [\[CrossRef\]](#)
13. Peño IC, Revilla VDH, Carbonell BP, Sacoto DD, Ferrer MEF, García-Cobos R, et al. Neurobehçet disease: clinical and demographic characteristics. *Eur J Neurol* 2012;19: 1224-7. [\[CrossRef\]](#)
14. Yoon DL, Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response. *Int J Rheum Dis* 2014;17: 453-8. [\[CrossRef\]](#)
15. Hentati F, Fredj M, Gharbi N, Hamida M. Clinical and biological aspects of neuro-Behçet's in Tunisia. In: Wechsler B, Godeau P, eds. Behçet's disease. Amsterdam, Elsevier, 1993, pp415-8.
16. Bohlega S, AlKawi MZ, Omer S. Neuro-Behçet's: clinical syndromes and prognosis. In: Wechsler B, Godeau P, eds. Behçet's disease. Amsterdam, Elsevier, 1993, pp 429-33.
17. Nakamura Y, Takahashi M, Ueyama K, Mitsui Y, Tanaka H, Nishimoto K, et al. Magnetic resonance imaging and brain-stem auditory evoked potentials in neuro-Behçet's disease. *J Neurol* 1994;241: 481-6. [\[CrossRef\]](#)
18. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications of Behçet's syndrome. *Brain* 1999;122: 2183-94. [\[CrossRef\]](#)
19. Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. *J Neurol* 2001;248: 95-103. [\[CrossRef\]](#)
20. Lee SH, Yoon PH, Park SJ, Kim DI. MRI findings in neuro-Behçet's disease. *Clin Radiol* 2001;56: 485-94. [\[CrossRef\]](#)
21. Yucesan C, Isikay CT, Özay E, Aydın N, Mutluer N. The clinical involvement patterns of neuro-Behçet's disease. *Eur J Neurol* 2001;8: 92. [\[CrossRef\]](#)
22. Sbai A, Wechsler B, Duhaut P, Du-Boutin LT, Amoura Z, Cacoub P, et al. Neuro-Behçet's disease (isolated cerebral thrombophlebitis excluded). Clinical pattern, prognostic factors, treatment and long term follow-up. *Adv Exp Med Biol* 2003;528: 371-6. [\[CrossRef\]](#)
23. Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behçet's disease: a prospective study from Iraq. *J NeurolNeurosurg Psychiatry* 2003;74: 608-13. [\[CrossRef\]](#)
24. Turker H, Terzi M, Bayrak O, Cengiz N, Onar M, Us O. Visual evoked potentials in differential diagnosis of multiple sclerosis and neuro-Behçet's disease. *Tohoku J Exp Med* 2008;216: 109-16. [\[CrossRef\]](#)
25. Borhani-Haghighi A, Samangoie S, Ashjzadeh N, Nikseresht A, Shariat A, Yousefipour G, et al. Neurological manifestations of Behçet's disease. *Saudi Med J* 2006;27: 1542-6.
26. Lo Monaco A, La Corte R, Caniatti L, Borrelli M, Trotta F. Neurological involvement in North Italian patients with Behçet disease. *Rheumatol Int* 2006;26: 1113-9. [\[CrossRef\]](#)
27. Barros R, Santos E, Moreira B. Clinical characterization and pattern of neurological involvement of Behçet's disease in fifteen Portuguese patients. *Clin Exp Rheumatol* 2007;24: 31.
28. Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. *Clin Exp Rheumatol* 2007;25: 58-64.
29. Gökçay F, Celebisoy N, Gökçay A, Aksu K, Keser G. Neurological symptoms and signs in Behçet disease: a Western Turkey experience. *Neurologist* 2011;17:147-50. [\[CrossRef\]](#)
30. Mohammed RHA, Nasef A, Kewan HH, Al Shaar M. Vascular neurobehçet disease: correlation with current disease activity forum and systemic vascular involvement. *Clin Rheumatol* 2012;31:1033-40. [\[CrossRef\]](#)
31. Houman MH, Bellakhal S, Salem TB, Hamzaoui A, Braham A, Lamoum M, et al. Characteristics of neurological manifestations of Behçet's disease: A retrospective monocentric study in Tunisia. *Clin NeurolNeurosurg* 2013;115: 2015-8. [\[CrossRef\]](#)
32. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. *J Neurol* 2014;261:1662-776. [\[CrossRef\]](#)
33. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet's disease receiving ciclosporin therapy. *Ophthalmology* 1999;106:586-9. [\[CrossRef\]](#)
34. Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. *Clin Exp Ophthalmol* 2001;29:335-6. [\[CrossRef\]](#)
35. Kotter I, Gunaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A than under other medications-results of a retrospective analysis of 117 cases. *Clin Rheumatol* 2006;25:482-6. [\[CrossRef\]](#)
36. Akman-Demir G, Ayrançi O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporin for Behçet's uveitis: is it associated with an increased risk of neurological involvement? *Clin Exp Rheumatol* 2008;26:584-90.